A5023698350- Vitamin C and Antioxidants Research
- Colorectal Cancer Treatments and Studies
- Intraperitoneal and Appendiceal Malignancies
- Cancer Cells and Metastasis
- Vitamin D Research Studies
- Cancer Immunotherapy and Biomarkers
- Childhood Cancer Survivors' Quality of Life
- Digestive system and related health
- Ethics in Clinical Research
- Lung Cancer Treatments and Mutations
- Cancer Risks and Factors
- Nonmelanoma Skin Cancer Studies
- Cancer Genomics and Diagnostics
- Intraocular Surgery and Lenses
- Intestinal and Peritoneal Adhesions
- Cancer Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Cancer survivorship and care
- Chemotherapy-related skin toxicity
- Birth, Development, and Health
- Botulinum Toxin and Related Neurological Disorders
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Proteoglycans and glycosaminoglycans research
- Patient Dignity and Privacy
Sun Yat-sen University Cancer Center
2016-2024
Sun Yat-sen University
2016-2024
State Key Laboratory of Oncology in South China
2017-2023
The hematogenous metastatic pattern of gastric cancer (GC) was not fully explored. Here we analyzed the frequency and clinicopathological features metastasis to liver, lung, bone, brain from GC patients. Data queried for this analysis included patients Surveillance, Epidemiology, End Results Program database 2010 2014. All statistical analyses were performed using Intercooled Stata 13.0 (Stata Corporation, College Station, TX). tests two-sided. Totally, there 19 022 eligible analysis. At...
Abstract Purpose: To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus as first-line treatment in patients with metastatic colorectal cancer (mCRC). Patients Methods: Between 2017 2019, histologically confirmed mCRC (n = 442) normal glucose-6-phosphate dehydrogenase status no prior for disease were randomized (1:1) into a control (FOLFOX bevacizumab) an experimental [high-dose (1.5 g/kg/d, intravenously 3 hours from D1 to D3) bevacizumab] group....
Preclinical studies suggest synergistic effectiveness of ascorbic acid (AA, vitamin C) and cytotoxic agents in gastrointestinal malignancies. This phase 1 study aimed to establish the maximum tolerated dose (MTD) recommended 2 (RP2D) AA combined with mFOLFOX6 or FOLFIRI regimens patients metastatic colorectal cancer (mCRC) gastric (mGC). In dose-escalation phase, received (0.2–1.5 g/kg, 3-h infusion, once daily, days 1–3) a 14-day cycle until MTD was reached. speed-expansion administered at...
Abstract Serglycin is a proteoglycan that was first found to be secreted by hematopoietic cells. As an extracellular matrix (ECM) component, serglycin promotes nasopharyngeal carcinoma (NPC) metastasis and serves as independent, unfavorable NPC prognostic indicator. The detailed mechanism underlying the roles of in cancer progression remains clarified. Here, we report knockdown cells inhibited cell sphere formation tumor seeding abilities. downregulation enhanced high-metastasis sensitivity...
The prognostic value of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) has been extensively studied and verified by the CellSearch® system. Varieties microfluidic systems have developed to improve capture efficiency with lack standardization automation. This study systematically positive threshold for prognosis its guidance anti-HER2 therapy based on a novel automated system OmiCell®.
Recruitment rate of clinical trials in cancer patients is pretty low China. Little known about factors influencing trial recruitment Chinese patients. The aim present study to evaluate the barriers and facilitators participation among lymphoma China.From December 2014 August 2015, survey was carried out Department Medical Oncology Sun Yat-sen University Cancer Center. A self-made questionnaire used (N = 331) their attitude toward trials. included 2 parts: patients' basic information whether...
Abstract Background During immunotherapy treatment and survival, identifying symptoms requires a standardized validated assessment tool. The aim of this study was to translate, validate use the Chinese version Immunotherapy M.D. Anderson Symptom Inventory for Early-Phase Trials module (MDASI-Immunotherapy EPT) assess symptom burden cancer patients receiving in China. Methods MDASI-Immunotherapy EPT translated into using Brislin’s translation model back-translation method. In total, 312...
Totally implantable access port (TIAP) is a subcutaneously implanted, long-term infusion device that widely used in oncology patients. However, multiple needle insertions into TIAP may lead to pain, anxiety, and dread This study aimed compare the effectiveness of Valsalva maneuver, eutectic mixture local anesthetics (EMLA) cream, combination both relieving pain cannulations on TIAP.
Abstract Purpose Chemotherapy-induced nail pigmentation is a common adverse effect, but prospective studies focussing on its onset, recovery, and severity are few. We aim to evaluate the pattern of chemotherapy-induced in early-stage breast cancer patients by calculating comprehensive score based hyperpigmentation area color depth plate. Methods This prospective, observational study was conducted between February 2019 December 2019. Early-stage scheduled receive anthracyclines combined with...
<div>AbstractPurpose:<p>To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus as first-line treatment in patients with metastatic colorectal cancer (mCRC).</p>Patients Methods:<p>Between 2017 2019, histologically confirmed mCRC (<i>n</i> = 442) normal glucose-6-phosphate dehydrogenase status no prior for disease were randomized (1:1) into a control (FOLFOX bevacizumab) an experimental [high-dose (1.5 g/kg/d,...
<div>AbstractPurpose:<p>To compare the efficacy and safety of high-dose vitamin C plus FOLFOX ± bevacizumab versus as first-line treatment in patients with metastatic colorectal cancer (mCRC).</p>Patients Methods:<p>Between 2017 2019, histologically confirmed mCRC (<i>n</i> = 442) normal glucose-6-phosphate dehydrogenase status no prior for disease were randomized (1:1) into a control (FOLFOX bevacizumab) an experimental [high-dose (1.5 g/kg/d,...
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
Abstract Objectives: To translate, validate and use the Chinese version of Immunotherapy M.D. Anderson Symptom Inventory for Early-Phase Trials module (MDASI-Immunotherapy EPT) to assess symptom burden cancer patients receiving immunotherapy in China. Methods: The MDASI-Immunotherapy EPT was translated into using Brislin’s translation model back-translation method. In total, 312 Chinese-speaking colorectal were enrolled trial from August 2021 July 2022 after definitive diagnoses our center....